Starling Oncology, Inc.
NASDAQTotal Valuation
Starling Oncology, Inc. carries a market capitalization of 639.89M, placing it among publicly traded companies globally. Its enterprise value stands at 63.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 639.89M |
| Enterprise Value | 63.38M |
Share Statistics
Starling Oncology, Inc. currently has 99.97M shares outstanding.
| Shares Outstanding | 99.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 0.11 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 5.48 |
Financial Position
Starling Oncology, Inc. maintains a current ratio of 1.36, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -419.35, indicating conservative leverage, while an interest coverage ratio of -2.53 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.36 |
| Quick Ratio | 1.14 |
| Debt / Equity | -419.35 |
| Debt / EBITDA | -5.42 |
| Interest Coverage | -2.53 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -21.47 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 27.66 |
Stock Price Statistics
Starling Oncology, Inc.'s stock has gained approximately 10.34483% over the past 52 weeks. The 50-day moving average sits at 5.43, while the 200-day moving average is 3.94.
| Beta (5Y) | N/A |
| 52-Week Price Change | 10.34483% |
| 50-Day Moving Average | 5.43 |
| 200-Day Moving Average | 3.94 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Starling Oncology, Inc. generated 587.24M in revenue and converted that into -36.29M in net income, yielding earnings per share of -0.36. EBITDA reached -19.28M, while operating income came in at -26.09M.
| Revenue | 587.24M |
| Gross Profit | 92.17M |
| Operating Income | -26.09M |
| Pretax Income | -36.29M |
| Net Income | -36.29M |
| EBITDA | -19.28M |
| EBIT | -26.09M |
| Earnings Per Share (EPS) | -0.36 |
Balance Sheet
Starling Oncology, Inc. holds 41.09M in cash and equivalents against 104.48M in total debt, resulting in a net debt position of 38.77M. Total book value stands at -24.91M, with working capital of 34.05M providing operational flexibility.
| Cash & Cash Equivalents | 41.09M |
| Total Debt | 104.48M |
| Net Debt | 38.77M |
| Equity (Book Value) | -24.91M |
| Book Value Per Share | -0.25 |
| Working Capital | 34.05M |
Cash Flow
Starling Oncology, Inc. produced 328,000.00 in operating cash flow over the past twelve months. After subtracting -3.61M in capital expenditures, free cash flow totaled -3.29M - equivalent to -0.03 per share.
| Operating Cash Flow | 328,000.00 |
| Capital Expenditures | -3.61M |
| Free Cash Flow | -3.29M |
| FCF Per Share | -0.03 |
Margins
Starling Oncology, Inc. operates with a gross margin of 15.69, reflecting its pricing power and cost economics. The operating margin of -4.44 and net profit margin of -6.18 provide insight into operational efficiency.
| Gross Margin | 15.69 |
| Operating Margin | -4.44 |
| Pretax Margin | -6.18 |
| Profit Margin | -6.18 |
| EBITDA Margin | -3.28 |
Scores
Starling Oncology, Inc. posts an Altman Z-Score of 0.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.90 |